AbCellera Biologics Inc (ABCL) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

AbCellera Reports Full Year 2024 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in...

Form 8-K - Current report

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: 45th Annual TD Cowen Health...

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera (Nasdaq: ABCL) will announce its full year 2024 financial results on Thursday, February 27, 2025, and hold an earnings conference call...

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities